Beck Greener LLP, Fulwood House, 12 Fulwood Place, London WC1V 6HR, United Kingdom.
Beck Greener LLP, Fulwood House, 12 Fulwood Place, London WC1V 6HR, United Kingdom.
Int J Pharm. 2024 Aug 15;661:124462. doi: 10.1016/j.ijpharm.2024.124462. Epub 2024 Jul 11.
Three-dimensional printing (3D printing) or "additive manufacturing" first came to prominence in the field of engineering, in particular in the transport sector where the value of its fast and accurate prototyping and manufacture of spare parts was quickly recognised. However, over the last ten years, this revolutionary technology has disrupted established manufacture in an increasingly diverse range of technical areas. Perhaps the most unexpected of these is pharmaceuticals - not merely the manufacture of products such as surgically inserted implants, but also of dosage formulations themselves - now available in all manner of printed delivery forms and vehicles and showing promising control of release properties though 3D printing process choices. This review will provide an overview of how 3D printing technology has developed and expanded across technological boundaries during the past decade, with a closer look at the current opportunities and barriers to its widespread adoption, particularly in the medical and pharmaceutical sectors. Special attention has been paid to patents as a boost and barrier to the expansion of 3D printing in the medical and pharmaceutical sector, with a focus on the patent literature.
三维打印（3D 打印）或“增材制造”首先在工程领域崭露头角，特别是在运输领域，其快速、准确的零部件原型制造和制造价值很快得到了认可。然而，在过去的十年中，这项革命性的技术已经在越来越多的技术领域颠覆了传统制造。其中最出人意料的可能是制药业——不仅仅是手术植入物等产品的制造，还包括剂量配方本身的制造——现在可以通过各种打印输送形式和载体获得，并且通过 3D 打印工艺选择显示出有前景的释放性能控制。本文综述了过去十年中 3D 打印技术如何跨越技术边界发展和扩展，并更详细地探讨了其广泛应用的当前机会和障碍，特别是在医疗和制药领域。特别关注了专利作为推动和阻碍 3D 打印在医疗和制药领域扩展的因素，并重点关注了专利文献。
